allAfrica.com on MSN4h
Africa: A Jab That Could Protect Against HIV for a Year At a Time, and Other Highlights From Major ConferenceA single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
Zacks.com on MSN18h
GILD Stock Down on Report of Cut in HIV Prevention SpendingGilead Sciences takes a hit after a Wall Street Journal reports state that the Trump administration is looking to slash ...
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.
Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...
Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services department is mulling cuts to federal HIV prevention funding ...
The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...
As Gilead Sciences prepares to launch twice-yearly lenacapavir pre-exposure prophylaxis (PrEP) later this year, the company is also developing once-yearly formulations that could make an even greater ...
The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...
Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback